Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Definium Therapeutics Inc (Definium Therapeutics), formerly Mind Medicine MindMed Incclinical biopharmaceutical company that develops a new generation of therapeutics to address underlying causes of psychiatric and neurological disorders. The company’s pipeline products include DT120 ODT, a proprietary orally disintegrating tablet, which treats generalized anxiety disorder and major depressive disorder and DT402, the R-enantiomer of MDMA for autism spectrum disorder. Definium Therapeutics serves the healthcare sector through the advancement of specialized clinical research and drug development. It operates in the US, Switzerland, and Australia. Definium Therapeutics is headquartered in New York City, the US.
Headquarters
United States of America
Address
Suite 8500, One World Trade Center, New York City, 10007
Website
www.mindmed.co
Telephone
1 212 2206633
No of Employees
105
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
DFTX (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-69.1%
(2024 vs 2023)
Market Cap*
$5.9B
* As of and is in US$
Products and Services
| Products |
|---|
| Pipeline |
| DT120 ODT: Generalized Anxiety Disorder and Major Depressive Disorder |
| DT4022: Autism Spectrum Disorder |
Competitor Comparison
| Key Parameters | Definium Therapeutics Inc | Johnson & Johnson | Pfizer Inc | AbbVie Inc | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Switzerland |
| City | New York City | New Brunswick | New York City | North Chicago | Basel |
| State/Province | New York | New Jersey | New York | Illinois | Basel-Stadt |
| No. of Employees | 105 | 138,200 | 75,000 | 57,000 | 75,267 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Carol A. Vallone | Chairman | Executive Board | 2021 | 68 |
| Andreas Krebs | Vice Chairman | Executive Board | 2021 | 67 |
| Robert Barrow | Chief Executive Officer; Director | Executive Board | 2021 | 36 |
| Brandi Roberts | Chief Financial Officer | Senior Management | 2025 | - |
| Mark R. Sullivan | Secretary; Chief Legal Officer | Senior Management | 2023 | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer